Clinical Trial

VA Induction and Bridging Transplantation for Hypoplastic/Secondary AML

Name: VA Induction and Bridging Transplantation for Hypoplastic/Secondary AML — clinical trial record (NCT07635485)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting

View on ClinicalTrials.gov →

Summary

The purpose of this study is to explore the efficacy and safety of venetoclax combined with azacitidine（VA) induction followed by bridging allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of hypoplastic and secondary acute myeloid leukemia (AML).

Trial Details

NCT Number	NCT07635485
Lead Sponsor	The First Affiliated Hospital of Soochow University Collaborators: Nanfang Hospital, Southern Medical University, Ruijin Hospital North Shanghai Jiao Tong University School of Medicine
Conditions	Hypoplastic Acute Myeloid Leukemia, Secondary AML (Adult)
Enrollment	50 participants
Start Date	2026-06-01
Primary Completion	2029-05-31 (estimated)
Study Completion	2029-08-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-09